DOCSLIB.ORG

Improved Insulin Sensitivity with the Angiotensin II-Receptor Blocker Losartan in Patients with Hypertension and Other Cardiovascular Risk Factors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improved Insulin Sensitivity with the Angiotensin II-Receptor Blocker Losartan in Patients with Hypertension and Other Cardiovascular Risk Factors Journal of Human Hypertension (2006) 20, 860–866 & 2006 Nature Publishing Group All rights reserved 0950-9240/06 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors TA Aksnes1, HM Reims2, S Guptha3, A Moan4,IOs5 and SE Kjeldsen6 1Department of Cardiology, Ullevaal University Hospital, Oslo, Norway; 2Department of Cardiology, Ullevaal University Hospital, Oslo, Norway; 3Merck & Co., Whitehouse Station, New Jersey, USA; 4MSD AS, Drammen, Norway; 5Department of Nephrology, Ullevaal University Hospital, Oslo, Norway and 6Department of Cardiology, Ullevaal University Hospital, Oslo, Norway We aimed to compare the effects of two different a 4-week open-label wash-out phase, the participants vasodilating principles, angiotensin II-receptor blockade crossed over to the opposite treatment regimen and and calcium channel blockade, on peripheral insulin- final examinations with hyperinsulinaemic isoglycaemic mediated glucose uptake in patients with hypertension glucose clamp after another 8 weeks. Blood pressure and other cardiovascular risk factors. Twenty-one was lowered to the same level in both treatment periods. hypertensive patients (11 women and 10 men) with The glucose disposal rate was significantly higher after mean age 58.6 years (range 46–75 years), body mass treatment with losartan 100 mg þ amlodipine 5 mg com- index 29.271.0 kg/m2 and blood pressure 16073/ pared to amlodipine 10 mg (4.970.4 vs 4.270.5 mg/kg/ 9672 mm Hg entered a 4-week run-in period with min, P ¼ 0.039). Thus our data suggest that angiotensin open-label amlodipine 5 mg. Thereafter they were ran- II-receptor blockade with losartan improves glucose domized double-blindly to additional treatment with metabolism at the cellular level beyond what can be amlodipine 5 mg or losartan 100 mg. After 8 weeks of expected by the vasodilatation and blood pressure treatment, all patients underwent clinical examination reduction alone. and laboratory testing, and 17 of them underwent a Journal of Human Hypertension (2006) 20, 860–866. hyperinsulinaemic isoglycaemic glucose clamp. After doi:10.1038/sj.jhh.1002087; published online 21 September 2006 Keywords: angiotensin II type I receptor blockers; calcium channel blockers; diabetes mellitus; hypertension; insulin resistance Introduction angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II-receptor blockers (ARBs) and calcium Patients with hypertension have an increased pre- channel blockers (CCBs).4–6 Furthermore, the Val- valence of insulin resistance and an increased risk 1 sartan Antihypertensive Long-Term Use Evaluation of developing diabetes mellitus with ageing. As (VALUE) trial7 recently observed a 23% reduction in high blood pressure is encountered in more than 2 development of type II diabetes mellitus with ARB- 20% of the adult population and its management is based compared with CCB-based treatment in non- a priority in preventing cardiovascular complica- 3 diabetic hypertensive subjects. It thus appears that tions, antihypertensive strategies which also at- treatment with ARBs/ACEIs may prevent new-onset tenuate the trend towards diabetes mellitus might diabetes mellitus better than treatment with CCBs, have considerable clinical significance. Data from which is probably neutral in this aspect. The cohort and randomized trials suggest that the mechanism for the differential effects of the two incidence of type II diabetes mellitus is unchanged different vasodilating agents is, however, unclear, as or increased by thiazides and b-adrenergic blockers, both ARBs and CCBs lower blood pressure by whereas it appears to be unchanged or decreased by reducing peripheral resistance. To our knowledge, no double-blind, randomized study has previously compared the effects of ARB and CCB on insulin Correspondence: Dr TA Aksnes, Department of Cardiology, sensitivity using the hyperinsulinaemic isoglycae- Ullevaal University Hospital, N-0407 Oslo, Norway. mic glucose clamp in patients with essential E-mail: [email protected] Received 20 March 2006; revised 19 June 2006; accepted 19 July hypertension. We hypothesized that ARB therapy 2006; published online 21 September 2006 may have an additive effect and improve insulin Losartan and insulin sensitivity TA Aksnes et al 861 sensitivity more than CCB therapy alone at a At inclusion, blood pressure averaged 16073/ comparable dose with regards to the blood pres- 9672 mm Hg and heart rate 6672 beats/min. Body sure-lowering effect. mass index was 29.271.0 kg/m2 in the whole study group and the waist-to-hip ratio was 0.9270.01 in the women and 1.0570.01 in the men. Four patients Methods (19%) were previously untreated for their hyperten- sion and seven (33%) were previously treated with Study population thiazides, four (19%) with b-blockers and six (29%) Twenty-five patients with mild-to-moderate essen- with a CCB. Five (24%) subjects were smokers. Four tial hypertension (office diastolic blood pressure of the patients did not complete two glucose clamps 95–110 mm Hg and systolic blood pressure owing to technical problems during the clamp o180 mm Hg) were recruited from general practi- procedure. tioners in the city of Oslo. The participants were previously untreated for hypertension or treated with monotherapy, but not with ACEI or ARB. All had impaired glucose tolerance or impaired fasting Study design glucose defined as fasting plasma glucose 6.1– The present double-blind, randomized cross-over 7.0 mmol/l (110–126 mg/dl). The participants also study was designed to compare the metabolic effects had to have either microalbuminuria (urine albumin of 10 mg amlodipine and 100 mg losartan þ 5mg excretion rate X20 mg/min), dyslipidaemia (high- amlodipine (Figure 2). After a 4-week open-label density lipoprotein (HDL)-cholesterol o0.9 mmol/l amlodipine 5 mg run-in period, all hypertensive (35 mg/dl) or triglycerides 41.7 mmol/l (150 mg/ patients were randomized to additional treatment dl)), body mass index 428 kg/m2 or an increased with either amlodipine 5 mg or losartan 100 mg for 8 waist-to-hip ratio (40.9 for men, 40.85 for women). weeks. At the end of this 8-week treatment period, At the first visit a clinical examination and labora- patients underwent blood pressure measurement, tory testing with electrolytes, creatinine and thyroid blood sampling and a hyperinsulinaemic isoglycae- hormones were taken to screen for secondary mic glucose clamp. Following this was a 4-week hypertension. wash-out phase where they continued open-label Owing to side effects of the study medication, 5 mg amlodipine, and then they were crossed-over mainly ankle oedema, but also headaches, flushing to the opposite treatment regimen for another 8 and palpitation, three patients decided to withdraw weeks before the final examination with blood from the study in the run-in period and are not pressure measurement, blood sampling and hyper- included in the final analysis. One of the patients insulinaemic isoglycaemic glucose clamp. who completed the study was excluded from The study was approved by the National Commit- analysis owing to an error at the hospital pharmacy tees for Research Ethics in Norway and the Norwe- (the patient was given amlodipine 10 mg through- gian Medicines Agency, and the patients’ verbal and out). Thus, the final study population consisted of written informed consent to participate was ob- 21 subjects (Figure 1), 11 women and 10 men. tained from each patient before inclusion in the The mean age was 58.6 years (range 46–75 years). study. Figure 1 Study population. Journal of Human Hypertension Losartan and insulin sensitivity TA Aksnes et al 862 Figure 2 The double-blind randomized crossover design. All patients used open-label amlodipine 5 mg during the whole trial, and they were randomized double-blindly to additional treatment with either an extra amlodipine 5 mg or losartan 100 mg for the 8-week treatment periods (V1 ¼ visit 1 or at baseline, V2 ¼ visit 2 etc., PE ¼ physical examination, I/E ¼ inclusion/exclusion criteria, BP ¼ blood pressure). Hyperinsulinaemic isoglycaemic glucose clamp sensitivity has a coefficient of variation of 5% in our technique laboratory, as previously detailed.9,10 The hyperinsulinaemic isoglycaemic glucose clamp was performed after an overnight fast. Antecubital veins on the right and left arm were cannulated Blood pressure measurement and analytical methods with short Teflon catheters (Optiva 2, 18G; Medex Blood pressure was measured with a mercury Medical Ltd., Haslingden, UK). Both catheters were sphygmomanometer with adequate cuff size and kept open with intermittent infusion of isotonic after 5 min rest in sitting position. The pressure was saline, the total amount not exceeding 100 ml. measured at least three times and the values The hyperinsulinaemic isoglycaemic glucose registered were the mean of the two latest measure- clamp was preformed using a modification of the ments. Blood glucose during the hyperinsulinaemic method described by DeFronzo et al.8 The insulin isoglycaemic glucose clamp was measured with an infusion was prepared in a bag with 100 ml of 0.9% Accu-Chek Sensor (Roche Diagnostics GmbH, Man- saline. To prevent insulin from adhering to the nheim, Germany). Serum insulin and C-peptide plastics, 4 ml of saline was exchanged with 4 ml of concentrations were measured using enzyme im- whole blood. To the 100 ml bag, 30 IE of Insulin munoassays (DAKO Insulin and DakoCytomation C- Actrapid were added and the bag was shaken well. peptide. DakoCytomation Ltd, UK). For analysing The mixture was then drawn into a 50 ml syringe glycated haemoglobin (HbA1c) we used Roche and infused at a fixed rate of 0.001 IE/kg body Tinaquant immunoassay. weight/min. The fasting blood glucose level was The homeostasis model assessment for insulin determined as the average of three measurements. resistance (HOMA-IR) was calculated in fasting Glucose and insulin were infused through one conditions as serum glucose (mmol/l) multiplied catheter, whereas the other was used for blood by serum insulin (pmol/l) and divided with 135, as sampling.
Load more

Recommended publications
  • Homeostasis Model Assessment Closely Mirrors the Glucose Clamp
    Emerging Treatments and T e c h n o l o g i e s ORIGINAL AR T I C L E Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin Se n s i t i v i t y Studies in subjects with various degrees of glucose tolerance and insulin se n s i t i v i t y ENZO BONORA, MD, PHD FRANCESCA SAGGIANI, MD sulin sensitivity (7). However, this method GIOVANNI TARGHER, MD MARINA B. ZENERE, MD is laborious, expensive, and theref o r e un- MARIA ALBERICHE, MD TIZIANO MONAUNI, MD suitable for large-scale or epidemiological RICCARDO C. BONADONNA, MD MICHELE MUGGEO, MD studies. Several alternative methods to evaluate insulin sensitivity have been pro- posed during the last two decades (8–13), but, although generally less complex and less troublesome than the glucose clamp OB J E C T I V E — To evaluate whether the homeostasis model assessment (HOMA) is a rel i - technique, none of them is as simple as is able surrogate measure of in vivo insulin sensitivity in humans. ne c e s s a r y in large-scale studies involving RESEARCH DESIGN AND METHODS — In the present study, we compared insulin hu n d r eds or thousands of subjects. sensitivity as assessed by a 4-h euglycemic ( 5 mmol/l) hyperinsulinemic ( 300 pmol/l) clamp Homeostasis model assessment (HOMA) with HOMA in 115 subjects with various degrees of glucose tolerance and insulin sensitivity. of insulin sensitivity was proposed about 10 years ago as a simple and inexpensive alter- RE S U LT S — We found a strong correlation between clamp-measured total glucose disposal native to more sophisticated techniques and HOMA-estimated insulin sensitivity (r = 0.820, P 0.0001), with no substantial dif- (14).
    [Show full text]
  • Surrogate Measures of Insulin Sensitivity Vs the Hyperinsulinaemic–Euglycaemic Clamp: a Meta-Analysis
    Diabetologia (2014) 57:1781–1788 DOI 10.1007/s00125-014-3285-x META-ANALYSIS Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis Julia Otten & Bo Ahrén & Tommy Olsson Received: 9 December 2013 /Accepted: 28 April 2014 /Published online: 3 June 2014 # Springer-Verlag Berlin Heidelberg 2014 Abstract Conclusions/interpretation The revised QUICKI fasting sur- Aims/hypothesis We aimed to identify which surrogate index rogate measure appears to be as good as the OGTT-based of insulin sensitivity has the strongest correlation with the Stumvoll MCR, OGIS, Matsuda, Stumvoll ISI and Gutt indi- reference measurement, the hyperinsulinaemic–euglycaemic ces for estimating insulin sensitivity. It can therefore be rec- clamp (HEC), to determine which surrogate measure should ommended as the most appropriate index for use in large-scale be recommended for use in large-scale studies. clinical studies. Methods A literature search (1979–2012) was conducted to retrieve all articles reporting bivariate correlations between the Keywords Glucose . Hyperinsulinaemic–euglycaemic HEC and surrogate measures of insulin sensitivity (in fasting clamp . Insulin . Insulin sensitivity . Meta-analysis . Surrogate samples or during the OGTT). We performed a random effects markers meta-analysis for each surrogate measure to integrate the correlation coefficients of the different studies. Abbreviations Results The OGTT-based surrogate measures with the stron- FIRI Fasting insulin resistance index gest pooled correlations (r) to the HEC were the Stumvoll G0 Fasting glucose metabolic clearance rate (Stumvoll MCR; r=0.70 [95% CI HEC Hyperinsulinaemic–euglycaemic clamp 0.61, 0.77], n=5), oral glucose insulin sensitivity (OGIS; HOMA-%S HOMA of insulin sensitivity r=0.70 [0.57, 0.80], n=6), the Matsuda index (r=0.67 [0.61, (computer generated) 0.73], n=19), the Stumvoll insulin sensitivity index (Stumvoll I0 Fasting insulin ISI; r=0.67 [0.60, 0.72], n=8) and the Gutt index (r=0.65 IGT Impaired glucose tolerance [0.60, 0.69], n=6).
    [Show full text]
  • Relationships of Surrogate Indexes of Insulin Resistance with Insulin Sensitivity Assessed by Euglycemic Hyperinsulinemic Clamp and Subclinical Vascular Damage
    Metabolism Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000911 on 13 November 2019. Downloaded from Relationships of surrogate indexes of insulin resistance with insulin sensitivity assessed by euglycemic hyperinsulinemic clamp and subclinical vascular damage Teresa Vanessa Fiorentino ,1 Maria Adelaide Marini,2 Elena Succurro,1 Francesco Andreozzi,1 Giorgio Sesti3 To cite: Fiorentino TV, ABSTRACT Marini MA, Succurro E, et al. Introduction Insulin resistance plays a crucial role in Significance of this study Relationships of surrogate the pathogenesis of type 2 diabetes and cardiovascular indexes of insulin resistance disease. The triglyceride to high- density lipoprotein What is already known about this subject? with insulin sensitivity cholesterol (TG/HDL-C) ratio, visceral adiposity index ► The triglyceride to high- density lipoprotein choles- assessed by euglycemic terol (TG/HDL- C) ratio, visceral adiposity index (VAI), hyperinsulinemic clamp and (VAI), lipid accumulation product (LAP) and triglycerides × fasting glucose (TyG) index are surrogate measures lipid accumulation product (LAP) and triglycerides × subclinical vascular damage. fasting glucose (TyG) index have been developed as of insulin sensitivity based on anthropometric and/or BMJ Open Diab Res Care surrogate measures of insulin resistance based on 2019;7:e000911. doi:10.1136/ biochemical parameters routinely collected in clinical bmjdrc-2019-000911 practice. Herein, we compared the relationships of these anthropometric and/or biochemical parameters rou- four surrogate indexes with insulin sensitivity assessed tinely collected in clinical practice. by the gold standard euglycemic hyperinsulinemic clamp What are the new findings? ► Additional material is technique, and subclinical vascular damage. ► Among the four surrogate indexes of insulin resis- copyright.
    [Show full text]
  • Risk Factors for Feline Diabetes Mellitus
    Risk factors for feline diabetes mellitus Lars Slingerland 2008 1 Risk factors for feline diabetes mellitus Risicofactoren voor diabetes mellitus bij de kat (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. J.C.Stoof, ingevolge het besluit van het college van promoties in het openbaar te verdedigen op donderdag 7 februari 2008 des middags te 4.15 uur door Lars Ingmar Slingerland geboren op 30 mei 1974, te Willemstad (Curaçao). 3 Promotor: Prof. dr. A. Rijnberk Co-promotoren: Dr. T.W. van Haeften Dr. H.S. Kooistra 4 The studies in this thesis were conducted and financially supported by the Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. Printing of this thesis was financially supported by: A. Menarini Diagnostics Benelux AUV Dierenartsencoöperatie B. Braun Medical Eurovet Animal Health (Animal Pharm Awards Winner 2007) Intervet Merial Novartis Pfizer Animal Health Posthumafonds (Koninklijke Nederlandse Maatschappij voor Diergeneeskunde) Procter & Gamble Pet Care Proteq Dier en Zorg Verzekering Radiometer Nederland Druk: Ponsen en Looijen Slingerland, Lars Ingmar Risk factors for feline diabetes mellitus Lars Ingmar Slingerland, Utrecht Universiteit Utrecht, Faculteit Diergeneeskunde Thesis Universiteit Utrecht -- With references -- With summary in Dutch ISBN: 978-90-393-4742-3 Subject headings: diabetes mellitus, hyperglycemic glucose clamp,
    [Show full text]
  • The Effect of Cilostazol on Glucose Tolerance and Insulin Resistance in a Rat Model of Non-Insulin Dependent Diabetes Mellitus
    The Korean J ournal of Inte rnal Medicine Vol. 16, No. 2, J une , 2001 T h e Eff e ct o f C ilo s t a z o l o n G lu c o s e T o le r a n c e a n d In s u lin Re s is t a n c e in a Ra t M o d e l o f N o n - in s u lin De p e n d e nt Dia b e t e s M e llit u s S a n g A h C h a n g , M . D. , Bo n g Yu n C h a , M .D.*, S o o n J ib Yo o , M .D. , Yo o Ba e A h n , M .D., Ki Ho S o n g , M .D. , J e Ho Ha n , M .D., J o n g M in Le e , M .D. , Hy u n S ik S o n , M .D. , Ku n Ho Yo o n , M . D. , M o o IL Ka n g , M .D. , Kw a n g W o o Le e , M .D. , Ho Yo u n g S o n , M .D. , a n d S u n g Ku Ka n g , M .D. De p a rt m e nt of Inte rna l M e d ic ine , Cat ho lic Un iv e rs ity Me d ica l Co lle g e , S e o u l, Ko re a B a c kg ro u n d : It h as b e e n re p o rt e d t h at m a ny p e rip he ra l v a s o d ilat ing d rug s m ig ht im p ro v e ins u lin re s is t a n ce .
    [Show full text]
  • Glucose Metabolism in Patients with Psoriasis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Copenhagen University Research Information System Glucose metabolism in patients with psoriasis Friis, N. U.; Hoffmann, N.; Gyldenlove, M.; Skov, L.; Vilsbøll, T.; Knop, F. K.; Storgaard, H. Published in: British Journal of Dermatology DOI: 10.1111/bjd.17349 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Friis, N. U., Hoffmann, N., Gyldenlove, M., Skov, L., Vilsbøll, T., Knop, F. K., & Storgaard, H. (2019). Glucose metabolism in patients with psoriasis. British Journal of Dermatology, 180(2), 264-271. https://doi.org/10.1111/bjd.17349 Download date: 09. Oct. 2020 BJD REVIEW ARTICLE British Journal of Dermatology Glucose metabolism in patients with psoriasis* 1 1 2 2 1,3 1,3,4 1 N.U. Friis iD , N. Hoffmann, M. Gyldenløve, L. Skov iD , T. Vilsbøll iD , F.K. Knop iD and H. Storgaard iD 1Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, Kildegardsvej 28, DK-2900 Hellerup, Denmark 2Department of Dermatology and Allergology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark 3Department of Clinical Medicine and 4Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Summary Correspondence Background Epidemiological studies strongly suggest that psoriasis predisposes to Heidi Storgaard. type 2 diabetes. Several theories have been proposed to explain how these disease E-mail: [email protected] entities might be pathophysiologically connected. Objectives Our primary objective was to elucidate whether clinical data support the Accepted for publication 23 October 2018 notion of common pathophysiological denominators in patients with psoriasis and type 2 diabetes, and thus to delineate the association between the two condi- Funding sources tions that has arisen on the basis of epidemiological studies.
    [Show full text]
  • Validity and Reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and Mcauley’S Indices in Patients with Hypertension and Type II Diabetes
    Journal of Human Hypertension (2007) 21, 709–716 & 2007 Nature Publishing Group All rights reserved 0950-9240/07 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley’s indices in patients with hypertension and type II diabetes PA Sarafidis1,2, AN Lasaridis1, PM Nilsson3, MI Pikilidou1, PC Stafilas1, A Kanaki1, K Kazakos1, J Yovos1 and GL Bakris2 11st Department of Medicine, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece; 2Hypertension/Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA and 3Department of Medicine, Malmo¨ University Hospital, Lund University, Malmo¨, Sweden The aim of this study was to evaluate the validity and subjects’ body weight or fat-free mass and every other reliability of homeostasis model assessment-insulin clamp-derived index. 1/HOMA-IR and QUICKI indices resistance (HOMA-IR) index, its reciprocal (1/HOMA-IR), were positively correlated with the M-value (r ¼ 0.342, quantitative insulin sensitivity check index (QUICKI) and Po0.05 and r ¼ 0.456, Po0.01, respectively) and the rest McAuley’s index in hypertensive diabetic patients. In 78 clamp indices. McAuley’s index generally presented less patients with hypertension and type II diabetes glucose, strong correlations (r ¼ 0.317, Po0.05 with M-value). In insulin and triglyceride levels were determined after a multivariate analysis, HOMA-IR was the best fit of clamp- 12-h fast to calculate these indices, and insulin sensi- derived IS. Coefficients of variation between the two tivity (IS) was measured with the hyperinsulinemic visits were 23.5% for HOMA-IR, 19.2% for 1/HOMA-IR, euglycemic clamp technique.
    [Show full text]
  • Insulin Resistance in a Boy with Congenital Generalized Lipodystrophy
    003 1-399818812406-0668$02.00/0 PEDIATRIC RESEARCH Vol. 24, No. 6, 1988 Copyright O 1988 International Pediatric Research Foundation, Inc. Printed in U.S.A. Insulin Resistance in a Boy with Congenital Generalized Lipodystrophy HIROKAZU TSUKAHARA, KIYOSHI KIKUCHI, HIDESHI KUZUYA, EIKO ITO, YOKO ODA, ATSUSHI KOSAKI, TAKAKO KAKEHI, HARUO NISHIMURA, KAZUNURI YAMADA, YASUNAO YOSHIMASA, HIROO IMURA, AND HARUKI MIKAWA Department ofpediatrics [H.T. K.K., H.M.], Second Division, Department ofMedicine[H.K., A.K., T.K., H.N., K. Y., Y.Y., H.I.], Kyoto Municipal Toyo Hospital [E.Z., Y.0.1, Kyoto, Japan ABSTRACT. We have studied insulin resistance in a 12- CGL, a rare hereditary disease, was first documented by Ber- year-old Japanese boy who presented with congenital gen- ardinelli (I) and Seip (2). The clinical features are observed from eralized lipodystrophy. Oral glucose tolerance test exhib- birth or early infancy, and the hallmarks include a total lack of ited a diabetic pattern with normal fasting plasma glucose. fatty tissue, peculiar face, accelerated growth, muscular hypertro- Results from euglycemic glucose clamp study showed de- phy, acanthosis nigricans, hepatomegaly, and hypertrophied gen- creases in both insulin sensitivity and responsiveness. Both itals (1-10). In CGL, normal glucose tolerance is observed during the patient's erythrocytes and Epstein-Barr virus trans- the first few years of life. However, between the ages of 7 and 12 formed lymphocytes showed low-normal insulin binding yr, glucose intolerance ensues and insulin-resistant and nonke- with a slight reduction in binding affinity in the latter. totic diabetes mellitus develops in most cases (6-10).
    [Show full text]
  • Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-Up of Patients with Type 2 Diabetes
    Pathophysiology/Complications ORIGINAL ARTICLE Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes AKIRA KATSUKI, MD RIKA ARAKI-SASAKI, MD sex hormone–binding globulin (SHBG) YASUHIRO SUMIDA, MD YASUKO HORI, MD (2–10). Recently, the usefulness of HOMA- ESTEBAN C. GABAZZA, MD YUTAKA YANO, MD IR as an indicator of insulin resistance in SHUICHI MURASHIMA, MD YUKIHIKO ADACHI, MD diabetic patients has been the focus of MASAHIKO FURUTA, MD much attention (11–13). A significant cor- relation has been reported between the insulin resistance index calculated by HOMA and the hyperinsulinemic-eugly- cemic clamp (clamp IR) (11,12). OBJECTIVE — To investigate the usefulness of the homeostasis model assessment as an index We previously reported that the serum of insulin resistance (HOMA-IR) for evaluating the clinical course of patients with type 2 diabetes. levels of SHBG may be an index of insulin RESEARCH DESIGN AND METHODS — The usefulness of HOMA-IR and its rela- resistance only in the hyperinsulinemic state tionship with insulin resistance assessed by the hyperinsulinemic-euglycemic clamp study (before treatment) (7). The usefulness of (clamp IR) were evaluated in 55 Japanese patients with type 2 diabetes before and after treat- HOMA as an index of insulin resistance ment. The patients were subjected to diet (ϳ1,440–1,720 kcal/day) and exercise therapy (walk- during therapy of diabetes has not been as ing 10,000 steps daily) for 6 weeks during their hospitalization. yet evaluated. To evaluate this, in the pres- ent study, we investigated whether HOMA- RESULTS — Univariate regression analysis disclosed a significant correlation between log- IR is correlated with clamp IR before and Ϫ Ͻ transformed HOMA-IR and log-transformed clamp IR before (r = 0.613, P 0.0001) and after after treatment.
    [Show full text]
  • Zinc Supplementation for the Prevention of Type 2 Diabetes Mellitus (Review)
    Zinc supplementation for the prevention of type 2 diabetes mellitus (Review) Beletate V, El Dib R, Atallah ÁN This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Zinc supplementation for the prevention of type 2 diabetes mellitus (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 6 DISCUSSION ..................................... 7 AUTHORS’CONCLUSIONS . 7 ACKNOWLEDGEMENTS . 7 REFERENCES ..................................... 8 CHARACTERISTICSOFSTUDIES . 9 DATAANDANALYSES. 11 WHAT’SNEW..................................... 11 HISTORY....................................... 12 CONTRIBUTIONSOFAUTHORS . 12 DECLARATIONSOFINTEREST . 12 SOURCESOFSUPPORT . 12 INDEXTERMS .................................... 12 Zinc supplementation for the prevention of type 2 diabetes mellitus (Review) i Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Zinc supplementation for the prevention of type 2 diabetes mellitus Vânia Beletate1, Regina El Dib2, Álvaro N Atallah3 1Programa de graduacao de Medicina Interna e
    [Show full text]
  • Diagnostic Methods of Insulin Resistance in a Pediatric Population Azucena Martínez Basila, Jorge Maldonado Hernández and Mardia López Alarcón
    Bol Med Hosp Infant Mex 2011;68(5):367-373 pediatric theMe Diagnostic methods of insulin resistance in a pediatric population Azucena Martínez Basila, Jorge Maldonado Hernández and Mardia López Alarcón ABSTRACT Obesity is the main risk factor for insulin resistance (IR) in the pediatric population. IR represents a link between obesity and other metabolic complications such as type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Therefore, accurate diagnosis and early intervention may reduce the incidence of T2DM and CVD in at-risk individuals. In this study we describe the techniques used to assess insulin sensitivity in pediatric populations. We also describe in detail three diagnostic tests: the glucose clamp technique, which represents the gold standard to determine tissue insulin sensitivity and insulin secretion; HOMA and QUICKI, which are indexes obtained from fasting glucose and insulin concentrations; and ISI-Composite, obtained from an oral glucose tolerance test, which provides additional information on glucose metabolism after an oral glucose load. In conclusion, the glucose clamp technique is an invasive procedure that is difficult to use in routine clinical settings. Because the cut-off points to diagnose IR with values derived from ISI-Composite have not been established for pediatric populations, HOMA and QUICKI, despite their lack of precision, remain the most used in clinical practice. Key words: insulin resistance, diabetes mellitus, glucose. INTRODUCTION population5,6 because early diagnosis may reduce risks and delay onset of irreversible pathological entities. Obesity is the main risk factor for insulin resistance (IR) Insulin is a peptide hormone composed of 51 amino in the pediatric population.1 In Mexico, the national com- acids coded on the short arm of chromosome 11 and bined prevalence for overweight and obesity in children synthesized in the pancreas within β-cells in the islets of between 5 and 11 years old reaches 26%.
    [Show full text]
  • Carbohydrate Metabolism in the Elderly
    European Journal of Clinical Nutrition (2000) 54, Suppl 3, S112±S120 ß 2000 Macmillan Publishers Ltd All rights reserved 0954±3007/00 $15.00 www.nature.com/ejcn Carbohydrate metabolism in the elderly D Elahi1,2* and DC Muller2 1Massachusetts General Hospital, Geriatric Research Laboratory, Boston MA 02114, USA; and 2Gerontology Research Center, National Institute on Aging, Laboratory of Clinical Investigation, Baltimore MD 21224, USA In this short review we summarize the effect of age on glucose homeostasis. The concept of decreased glucose tolerance with increasing age is introduced, followed by evidence for this phenomenon. Speci®cally we review the evidence for changes in fasting glucose as a function of age and the effect of age on HbA1c. The role of age on hepatic glucose production and glucose uptake is then discussed in detail and we review the evidence that supports the concept that with advancing age hepatic glucose sensitivity to insulin is unaltered. We then review the large evidence for the role of age on the purported decrease in peripheral tissue sensitivity to insulin and conclude that the issue is unsettled. The decrease attributed to age is no longer signi®cant when confounders are controlled for, the largest being obesity. We next present evidence that b-cell sensitivity to glucose remains intact with aging. A review of age-related disorders due to hyperglycemia and confounding effects on the relationships of age and glucose tolerance is presented next. Finally we present new evidence that when the revised criteria for the diagnosis of type 2 diabetics as proposed by the American Diabetes Association and WHO are used, a greater percentage of the elderly will not be diagnosed.
    [Show full text]